Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

October 14, 2023 0

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics (NTLA) announced that the European Medicines Agency …

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

October 11, 2023 0

Inovio Receives FDA Feedback for INO-3107 INOVIO (INO) - a biotechnology company focused on developing and …

Akero Therapeutics’ October 10, 2023 Press Release

October 10, 2023 0

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, …

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

October 9, 2023 0

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated …

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

October 6, 2023 0

Apellis Pharmaceuticals Launch Update of SYFOVRE® On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update …

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

October 5, 2023 0

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ …

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

October 4, 2023 0

Akero Therapeutics Akero Therapeutics (AKRO) announced publication in The Lancet Gastroenterology & Hepatology of results from …

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

September 28, 2023 0

Soleno Therapeutics Soleno Therapeutics (SLNO) is focused on the development and commercialization of novel therapeutics for …

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

September 26, 2023 0

Pliant Therapeutics in the NEWS Treating Primary Sclerosing Cholangitis Pliant Therapeutics (PLRX) today announced positive data …

Reata Stock Holders Approved the Firm’s Merger with Biogen

September 21, 2023 0

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary …

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

September 21, 2023 0

CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) - …

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

September 18, 2023 0

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene …

Discovering The Root Causes of Diseases

September 15, 2023 0

Prohost Letter #457 Discovering The Root Causes of Diseases Biotech firms with solid scientific fundamentals …

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

September 12, 2023 0

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 …

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

September 11, 2023 0

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

August 23, 2023 0

Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination …

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

August 21, 2023 0

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd